Projected >80% Oral Bioavailability
>80%
Overcoming legacy peptide barriers via thermodynamically-optimized molecular delivery modeling.
Legacy peptide absorption disrupted
Exclusive licensing dossier
NCS-004: Breaking the Oral Absorption Barrier in GLP-1R / GIP / GCG Tri-Agonism
Disrupting the legacy ~1% oral delivery threshold with high-efficiency small-molecule architecture. Scalable oral format designed for mass-market Obesity and Metabolic Syndrome intervention.
Evidence Grid
A compressed technical snapshot designed for executive licensing review.
Institutional-grade validation
Proprietary Low-Step Green Synthesis
Low-Step
High-yield, ESG-aligned manufacturing eliminating heavy metal catalysis.
ESG-aligned manufacturing
Disruptive Unit Economics
Unit Econ
Fractional unit production cost vs. peptide cold-chain standards. Engineered for global OTC and mass-scale accessibility.
Global mass-scale accessibility
High-Dimensional Fidelity: The NovaCore Systems Engine
Institutional-grade molecular architecture powered by advanced topological heuristics.
NovaCore Systems QVM Engine
At the core of our discovery process is the NovaCore Systems QVM Engine. Unlike conventional modeling paradigms, our proprietary framework operates in ultra-high-dimensional vector spaces, utilizing advanced topological heuristics to navigate an astronomical combinatorial state space. This closed-loop validation framework delivers unprecedented molecular fidelity and a low-step green synthesis blueprint, achieving industrial scalability where classical R&D stalls. Bridging massive computational modeling into validated thermodynamic stability and high-yield physical synthesis.
Market Comparison
A licensing-focused view of the measurable advantage versus the current injectable standard.
| Parameter | NCS-004 | Current Injectable Standard |
|---|---|---|
| Bioavailability | Projected >80% oral bioavailability (Overcoming legacy peptide barriers) | Injection-dependent; oral formats historically ~1% absorption barrier |
| Patient Compliance | Oral regimen aligned with mass-market adherence | Needle fatigue; cold-chain and injection training burden |
| Scalability | Disruptive unit economics engineered for global mass-scale | Higher device + logistics cost; constrained throughput |
| Process & ESG | Proprietary low-step green synthesis (eliminates heavy metal catalysis; ESG-aligned manufacturing) | Higher solvent load; legacy process constraints |
Tip: swipe horizontally on mobile for full table visibility.
Urgency & Strategy
Time-sensitive positioning designed for a decisive licensing outcome.
IP Priority Established
January 2026 • Priority lock with structured global route
High-contrast positioning for strategic partners seeking rapid market entry: enforceable IP sequencing, clean licensing scope, and a compliance-first disclosure pathway.
180-Day Global Licensing Exit
-
Days 1–45 • Strategic Outreach & Mutual NDA ExecutionGate 01
Targeted outreach, mutual NDA execution, and controlled entry to the VDR.
-
Days 46–105 • Deep-Dive Technical Due Diligence & VDR AuditGate 02
Deep-dive technical diligence, replication review, and VDR audit.
-
Days 106–150 • Binding Offer Submission & Final NegotiationsGate 03
Binding offer submission, definitive terms, and final negotiations.
-
Days 151–180 • Asset Transfer, Escrow Closing & Global Licensing HandoverGate 04
Asset transfer, escrow closing, and global licensing handover.
Trust & Security
Technical logs, raw datasets, and replication artifacts are only released under a signed mutual NDA.
Controlled Disclosure Protocol
Access is compartmentalized by role and timestamp. Confidential materials are watermarked and recorded to preserve integrity across multi-party due diligence.